Carboplatin

Catalog No.S1215 Synonyms: JM-8, CBDCA, NSC 241240

Carboplatin Chemical Structure

Molecular Weight(MW): 371.25

Carboplatin is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells.

Size Price Stock Quantity  
USD 77 In stock
USD 107 In stock
USD 167 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 11 Publications

5 Customer Reviews

  • Cell lines were exposed to the indicated concentrations of carboplatin (A) for 72 hours. Cell viability was assessed by alamarBlue assay and data recorded as fluorescence units at 590 nm. Data are presented as mean μM ± S.E.M. required to inhibit cell viability by 50%, in a minimum of three independent experiments.

    Cancer Lett, 2018, 436:75-86. Carboplatin purchased from Selleck.

    (A) The BRCA1-mutated TNBC cell lines MDA-MB-436 and HCC1937 were treated with CBP (10 μM) plus GEM (100 nM) combined with or without olaparib (10 μM) for the indicated times, and then, the cell viability was determined with an MTT assay. The results show data from six independent experiments expressed as the mean ± SD. p < 0.05.

    Sci Rep, 2017, 7:42319. Carboplatin purchased from Selleck.

  • Detection of apoptotic responses was found to increase in epimorphin-treated  A1847 with increasing concentrations of carboplatin compared to those of the untreated controls. Data were normalized to the controls and are represented as means ± S.D. [*p<0.05 compared with control]. Images of apoptotic cells were captured at 10X magnification, with at least 3 images per well, using an upright phase-contrast microscope (T3.15A; Fisher Scientific).

    PLoS One 2012 8, e72637. Carboplatin purchased from Selleck.

    A. MCF10A-Ras overexpressing a vector control or the gene of interest (GeneX), or MCF7 expressing a scramble or a siRNA for the geneX were treated with DMSO or with Carboplatin for 24h. Resistant colonies were allowed to grow for 2 weeks, and are then stained with Crystal Violet. B. Quantification of the results.

     

     

    Dr. Helen Sadik of Johns Hopkins University. Carboplatin purchased from Selleck.

  • Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Carboplatin for 48h. Cell survival was measured by a standarad MTT assay.

     

     

    Dr. Helen Sadik of Johns Hopkins University. Carboplatin purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Carboplatin is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells.
Features A DNA synthesis inhibitor.
Targets
DNA synthesis [1]
(A2780, SKOV-3, IGROV-1, HX62 cells)
In vitro

Carboplatin exhibits an inhibitory effect on cell proliferation in a human ovarian cancer cell line panel, including A2780, SKOV3, and IGROV-1 cells with IC50 of 6.1 μM, 12.4 μM and 2.2 μM, respectively. [1] Carboplatin also show the anti-proliferative activities in lung carcinoid cell line, such as UMC-11, H727, and H835 cells with IC50 of 36.4 μM, 3.4 μM and 35.8 μM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Tca8113/ut  NFz1XIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGK0bmQzNTJ34pEJ{txO NGPsbI84OiCq Mly1bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? Mnq0NlYyOzdzMEW=
Tca8113/CBP  NGm5UXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXHOYpwOi1{NfMAje69VQ>? MorkO|IhcA>? M4\kV4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NGnkdXgzPjF|N{GwOS=>
Tca8113/PYM  MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrhNk0zPeLCid88US=> MVK3NkBp NIjYfZpqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MojuNlYyOzdzMEW=
SKOV3 MljJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrZOlAhdWdxbXy= NWjpUG9iOS13IHS= MW\pcohq[mm2czDj[YxtKH[rYXLpcIl1gSC2aX3lJIRmeGWwZHXueIx6 Ml\INlYyOzdyNEO=
SKOV3 NWXHeWtyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\GUVAuPCEQvHevcYw> NUXqWXI6OjRxNEivO|IhcA>? NX\Reo1RcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnSueR?= NWnZfoJ{OjZzMkWyO|M>
SKOV3 M3TN[WFxd3C2b4Ppd{BCe3OjeR?= MUKyJO69\y:vbB?= M3TydlQ5KGh? NX7WboRNcW6mdXPld{BieG:ydH;zbZM> M3fETlI3OTJ3Mkez
OSA NGjXRoREdG:wb3flcolkKEG|c3H5 M{jU[VIvPS93IN88US=> MUTy[ZN2dHS|IHnuJIxwf2W{IHPvcI9vgSCob4LtZZRqd25iYYOgZ49ueGG{ZXSgeI8h\Wm2aHXyJGJOUTFic3nSUmEhfHKnYYTt[Y51 NEHQVIYzPjFzME[yNC=>
A549 MYjGeYN1cW:wIFHzd4F6 NYXkWHl7OC9{NT:1NEDPxE1? MXOyOEBp Mort[I94dnKnZ4XsZZRmeyCvaWKtNlA2KGW6cILld5Nqd28EoB?= NXLheXdwOjV7MUezNVc>
H1975 NHGxdY5HfWO2aX;uJGF{e2G7 Mo[0NE8zPS93MDFOwG0> Ml7sNlQhcA>? MYjkc5dvemWpdXzheIV{KG2rUj2yNFUh\XiycnXzd4lwdsLi MVuyOVkyPzNzNx?=
A549 MleySpVkfGmxbjDBd5NigQ>? NWqz[YR[OC9{NT:1NEDPxE1? M3jmUVI1KGh? M3O1ZpVxemWpdXzheIV{KG2rUj2yNVgh\XiycnXzd4lwdg>? M{nGW|I2QTF5M{G3
H1975 MmrjSpVkfGmxbjDBd5NigQ>? NGH0TocxNzJ3L{WwJO69VQ>? Ml3ENlQhcA>? NFnhbZd2eHKnZ4XsZZRmeyCvaWKtNlE5KGW6cILld5Nqd25? M4rHRVI2QTF5M{G3
A549 NX3nXWNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUK1OHhDOjVizszN MX6yOEBp MWnpcohq[mm2czDj[YxtKGe{b4f0bC=> M{ftOVI2QTF5M{G3
H1975 NHTLbpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;1S2QzPSEQvF2= M2\LeFI1KGh? NHz4PGpqdmirYnn0d{Bk\WyuIHfyc5d1cA>? NVTC[HJPOjV7MUezNVc>
MDA-MB-231 NHHyNVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrX[5kxNTJ{MDFOwIcwdWx? NVfXNWdsPzJiaB?= NUCyPVlPUUN3MNMgQUA5PiEQvF2= NF\E[oczPTh|N{[5NS=>
T47D NVjk[G5NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnWVHNOOC1{MkCg{txoN22u MoLGO|IhcA>? MnvpTWM2OMLiPTC0PE46KM7:TR?= MWGyOVg{PzZ7MR?=
LCTCC M3TNfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfNeIhKSzVyPUOuPQKBkcL3TR?= MYOyOVc4OzF4Nx?=
MCTCC M{Dte2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXRTWM2OD1{LklihKnDvU1? MkHvNlU4PzNzNke=
MegTCC MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYS1NWpQUUN3ME20MlHjiIoEtV2= NInydHMzPTd5M{G2Oy=>
MonoTCC M2flO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYCxe|BvUUN3ME21MlbjiIoEtV2= NFrJc4wzPTd5M{G2Oy=>
MCF7 NEDsfGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUSyNEDPxE1? MoDDO|IhcA>? NX6xZVRMcW6mdXPld{Bk\WyuIHTlZZRpKG:oIFjQNe6zNWSncHzleIVlKE2FRkegZ4VtdHN? MXuyOVc3QTB{NR?=
A-549  MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\zVJVlOC53IN88US=> Mn[yNlQhcA>? NFi1ZXhFVVORwrC= NXnOSGZNcW6qaXLpeJMh[2WubDDndo94fGhic3nncolncWOjboTsfS=> MXmyOVc2PTZ7MB?=
A-549  M4PMN2Fxd3C2b4Ppd{BCe3OjeR?= MmXSNE42KM7:TR?= MXW0PEBp NXjlOFBbTE2VT9Mg Ml6yd4hwf3NiZXHycJkh[XCxcITvd4l{KG[nYYT1doV{KGmwY3z1[Ilv\yCkbHXiZolv\yCjbnSgZ4hzd22jdHnuJINwdmSnboPheIlwdg>? MYWyOVc2PTZ7MB?=
A-549  NHPwWG5HfWO2aX;uJGF{e2G7 NY\yb|hbOC53IN88US=> MUW0PEBp MmjzSG1UV8Li Ml;ad4hwf3NiYXLldpJidnRibXnjdo91fWK3bHWg[Il{enWydHnvci=> M3rwflI2PzV3Nkmw
A-549  NWHyO4ZVTnWldHnvckBCe3OjeR?= NEfx[4IxNjVizszN NYDTVGlzPDhiaB?= NFPD[mFFVVORwrC= MoLPbY5pcWKrdIOgc4Yh[2WubDDtbYdz[XSrb39CpC=> NFTadlUzPTd3NU[5NC=>
RMG-1 MlztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTye5JYUUN3ME2yPE45KMLzIEOuOkBu\y:O MkXINlU4OjZ7MUO=
FN-RMG-1 NWnYVWdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX:0Z3pbUUN3ME20NE42KMLzIESuNkBu\y:OCjFOwG0> MUmyOVczPjlzMx?=
RMG-1-hFUT NFnod5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\NVmpbUUN3ME21PE4yKMLzIEKuOEBu\y:O MVSyOVczPjlzMx?=
FN-RMG-1-hFUT NVLMXlZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHT2R3pKSzVyPUGxPE45KMLzIEGzMlghdWdxTB?= NHnYW2IzPTd{NkmxNy=>
CHP-134  MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXHPFQ{OSEQvF2= M2rpfWROW00EoB?= MX\pcohq[mm2czDzbYdvcW[rY3HueEBk\WyuIHfyc5d1cCClb33ibY5m\CC5aYToJGdUUzJ6M{CzO|E> NXSxR2FDOjV4NUi0OlM>
IMR-32 NFm5R2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHI[FFvOSEQvF2= M4DJT2ROW00EoB?= M3Hzb4lvcGmkaYTzJJNq\26rZnnjZY51KGOnbHyg[5Jwf3SqIHPvcYJqdmWmIIfpeIghT1ONMkizNFM4OQ>? MoTENlU3PTh2NkO=
CHP-134  M{nYbGZ2[3Srb36gRZN{[Xl? NVrUfmg1OTBizszNxsA> NHjhTlNFVVORwrC= Mn7FbY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJGdUUzJ6M{CzO|E> NVu5bpRzOjV4NUi0OlM>
IMR-32 NFfwSJJHfWO2aX;uJGF{e2G7 NIrTTmIyOCEQvF5CpC=> M2Hz[GROW00EoB?= NX;pbYRJcW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKEeVS{K4N|A{PzF? MUmyOVY2QDR4Mx?=
A549 NYLJRZFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTMV4J[OC5{LUSwNFAh|ryP M1jZTVczKGh? MVHJR|UxRTF{NjFCtUA2NjBizszN M1HydlI2PjJ3MkSz
A549/CDDP NUXpeVl3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULrV|ZJOC5{LUSwNFAh|ryP NXvEUYExPzJiaB?= MYjJR|UxRTJ2MNMgxtHDqDR3Lkeg{txO MVOyOVYzPTJ2Mx?=
H460  MoqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnaNlQhcA>? MUXEUXNQ MVjJR|UxRTdwOTFOwG0> NHezXHUzPTV7OUm5OS=>
H460  NXe5b3doT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUftWHRLPy57IN88US=> Mom5NlQhcA>? MmG4SG1UVw>? MXrzbI94eyCjIILh[Ilwe2Wwc3n0bZpqdmdiZX\m[YN1KHSxIGitdoF6ew>? MXWyOVU6QTl7NR?=
NRK-52E M2HUWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LNbFczyqCqwrC= NV;DZWdLUUN3ME2xNFAhyrFiMUKuPUDPxE1? MUOyOVU3PTZyMx?=
RGE NWW3R3dxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVG1OppRPzMEoHlCpC=> NE\lSIFKSzVyPUKyJOKyKDdwNDFOwG0> M3zXelI2PTZ3NkCz
NRK-52E MortS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlX3O|LDqGkEoB?= M1HHfGlEQDB;MUe5JOKyKDlwNTFOwG0> M1zIRlI2PTZ3NkCz
RGE NYq0cmJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVq3NuKhcMLi NFPWXXNKSzhyPU[zJOKyKDdwNDFOwG0> NGSzfIUzPTV4NU[wNy=>
SK-OV-3 MoXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2e1NVczKGh? M{SxTWlEPTB;MUC0Mlgh|ryP MkSyNlU2OjBzM{K=
ES-2 NF3rXI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYGzcFhrPzJiaB?= MnL0TWM2OD1zND62JO69VQ>? NIXEUWczPTV{MEGzNi=>
OVCAR-8 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnFOoc4OiCq NUj6O|NTUUN3ME25Ok4xKM7:TR?= MWqyOVUzODF|Mh?=
3AO NYSzSlB7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVH6XpJRPzJiaB?= NW\nSWV4UUN3ME22N{41KM7:TR?= NHnC[WUzPTV{MEGzNi=>
A2780 MkLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2j1U|czKGh? M3fIWmlEPTB;MUS1Mlch|ryP MUCyOVUzODF|Mh?=
SW626 MmjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHPO|IhcA>? NGOzRXRKSzVyPUm3MlAh|ryP NVP4T4huOjV3MkCxN|I>
OVCAR-3 M37OdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVz0eY5oPzJiaB?= NI\tc2FKSzVyPUOyMlYh|ryP M2XkOlI2PTJyMUOy
A549 NGPTS2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTCfIpRUUN3ME2xOVEvPTZiwsGgOVMvODZizszN MYiyOVI4PzR4MR?=
4T1 NH76T2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTh2Lk[yJOKyKDNyLkC1JO69VQpizszN M1rzO|I2Ojd5NE[x
BALB/3T3 M1TpcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDNVHNKSzVyPUG0MlMxKMLzIE[uOlgh|ryP MYGyOVI4PzR4MR?=
B16 Mn;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGn2boZKSzVyPU[0MlMxKMLzIE[uPFEh|ryP MmXONlUzPzd2NkG=
DU 145 M{juZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUntVYN3UUN3ME2zOU4xPCEEsTCxO{42PCEQvF2= MnHUNlUzPzd2NkG=
FaDu NIHPWFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnaTWM2OD12NT6zPUDDuSBzMT61NEDPxE1? MUSyOVI4PzR4MR?=
HCV-29T MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7O[nBYUUN3ME20PE42PyEEsTCyNk41QSEQvF2= MWKyOVI4PzR4MR?=
HL-60 M13teWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHHcI9{UUN3ME2xNU4yOCEEsTC0MlQ4KM7:TR?= Mo\RNlUzPzd2NkG=
HT-29 NG\6UHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\FVnpKSzVyPUi5MlE3KMLzIEG4Mlg3KM7:TR?= MVSyOVI4PzR4MR?=
H146 NIXHNFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWX6[pVTUUN3ME20PU43yrFzMz6xJO69VQ>? MVGyOVEzPDJ6Mh?=
H187 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPFUpl7UUN3ME2xNk44yrF{Lkeg{txO MUmyOVEzPDJ6Mh?=
H128 M3frSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX6z[mNUUUN3ME2xNFYvPMLzOT62JO69VQ>? NWrkTYtiOjVzMkSyPFI>
H69 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnRdHhnUUN3ME23Ok46yrF{Nz64JO69VQ>? MlLFNlUyOjR{OEK=
H209 Mlm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrxTWM2OD1{NUiuNeKyQTlwODFOwG0> MXqyOVEzPDJ6Mh?=
DMS153 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jaXmlEPTB;NUeuPOKyQS5{IN88US=> M2LoTlI2OTJ2Mkiy
H526 NHLPOGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk[xTWM2OD15LkNCtVEvPyEQvF2= MXuyOVEzPDJ6Mh?=
DMS114 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIeyd|RKSzVyPUi1MljDuTF{Lkig{txO M{H3N|I2OTJ2Mkiy
DMS53 M3rkeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfOZWFHUUN3ME2xOFYvOsLzM{[uOEDPxE1? MUGyOVEzPDJ6Mh?=
HeLa NWPvWHN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW[1MVgxKM7:TR?= MlvGbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NHvpV5IzPTFyOUO2NC=>
MCF-7 NF;YbnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXDfWs2NThyIN88US=> MVvpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NYq0[3hxOjVzMEmzOlA>
MDA-MB-231 M3[wcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHiOU05OCEQvF2= NHLG[4JqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NXzGPFlmOjVzMEmzOlA>
CaOV3 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV23NkBp MorjTWM2OD16Nj6xJO69VQ>? MnnONlUxPjh6NEm=
OVCAR-3 NInBXoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HaUVczKGh? MkPaTWM2OD1zN{muOUDPxE1? Mlz2NlUxPjh6NEm=
OVCAR-5 NXnKd|NFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37SOlczKGh? NUTMW2NlUUN3ME23OU44KM7:TR?= M3TSWVI2ODZ6OES5
SKOV-3 NWT1dGRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfzR3N5PzJiaB?= Ml3VTWM2OD13MESg{txO MV2yOVA3QDh2OR?=
OVCAR-4 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\rdIlPPzJiaB?= M3rCfmlEPTB;MkmwMlYh|ryP MXqyOVA3QDh2OR?=
OVCAR-8 NEWyWXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4r0[lczKGh? NWH4Uo55UUN3ME22PVAvOiEQvF2= NYLXVm14OjVyNki4OFk>
MA148 M3vwTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XLXlI1KGh? MYTJR|UxRTh|LkdihKnDueLCiUGuOEDPxGdxbXy= M1W5bVI1QDNzMEmx
A549 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zKT|I1KGh? MVzJR|UxRTd5Nj6w5qCKyrIkgJmxMlkh|rypL33s MlTGNlQ5OzFyOUG=
MDA-MB-231 M4PRS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fGRVI1KGh? NGr4SmtKSzVyPUe0PE4x6oDLwsJihKkyNjFizsznM41t MnP5NlQ5OzFyOUG=
NCI-ADR/RES  MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVKyOEBp NHLOOYlKSzVyPUG3OVMvOOLCidMx5qCKPC52IN88[{9udA>? M1;ZXlI1QDNzMEmx
MA148 MlH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVm0PEBp NV;Fb3FLUUN3ME2yPE4y6oDLwsJihKkyNjBizsznM41t NWe0XmRWOjR6M{GwPVE>
A549 M4CyOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;XU2twPDhiaB?= MUDJR|UxRTFzOD6w5qCKyrIkgJmxMlIh|rypL33s Mn:5NlQ5OzFyOUG=
MDA-MB-231 M{f5WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4O0SFQ5KGh? NULNUpBlUUN3ME2xPFMvOOLCidMx5qCKOS5{IDFOwIcwdWx? NFHpeXEzPDh|MUC5NS=>
NCI-ADR/RES  MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIL1W|A1QCCq NF3zZVJKSzVyPUG5N{4x6oDLwsJihKkyNjlizsznM41t M3WzNlI1QDNzMEmx
MA148 MnK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1z1UVczKGh? NVrwdIxDUUN3ME2xN{446oDLwsJihKkyNjJizsznM41t NF7DSJAzPDh|MUC5NS=>
A549 Mn73S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGT5S204OiCq MULJR|UxRTZ2LkRihKnDueLCiUGuNUDPxGdxbXy= M1L2VlI1QDNzMEmx
MDA-MB-231 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVP2WI0{PzJiaB?= MXXJR|UxRTl7LkZihKnDueLCiUGuNUDPxGdxbXy= M4OzdVI1QDNzMEmx
NCI-ADR/RES  M37CTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGL2Spg4OiCq MVLJR|UxRTN5LkVihKnDueLCiUGuO{DPxGdxbXy= MXKyOFg{OTB7MR?=
A549 M2nhd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV63NkBp NGfhXYVFVVOR MljTTWM2OD1zNUKuOFA6KM7:TR?= NEXXfHYzPDd{MUOyNy=>
NCI-H157 Moq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfnXYg4OiCq MVzEUXNQ NFHkTItKSzVyPUi5Mlk4PyEQvF2= NYXEXXF{OjR5MkGzNlM>
PC9 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXi3NkBp NHnxdnlISzVyPUexMlbDuTlwNTFCuW0> NWKyeJdkOjR4MUi4NFk>
A549  Ml76S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGH5RmY4OiCq MonsS2M2OD1zM{dCtVMyNjZiwsXNxsA> MlHoNlQ3OTh6MEm=
PC9 MnXyRZBweHSxc3nzJGF{e2G7 MlHjNVAxKML3TR?= NV6xZ5dnPzJiaB?= MVPpcoR2[2W|IHHwc5B1d3Orcx?= MV[yOFYyQDhyOR?=
A549  M2LGd2Fxd3C2b4Ppd{BCe3OjeR?= M4W0eFExOCEEtV2= MljqO|IhcA>? M4\qeIlv\HWlZYOgZZBweHSxc3nz NFXmXpkzPDZzOEiwPS=>
A549 M4TIVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDDNlQhcA>? MXjJR|ExRTFwNEe2JI5O NF;6TWIzPDN7NkSzOy=>
H1299 NWDhZoFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXmNlQhcA>? Mn;jTWMyOD1yLkS0N{BvVQ>? NUPERoZjOjR|OU[0N|c>
HCC15 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXGyOEBp MmrsTWMyOD1yLkO0OkBvVQ>? MUWyOFM6PjR|Nx?=
H157 MnnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUWyOEBp M{HTWGlEOTB;MD64NUBvVQ>? M3nPVlI1Ozl4NEO3
A2780 M{jWN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XkXWlEPTB;MUSuNQKBkcLz4pEJNU41KM7:TR?= MnzpNlQzODl4OUO=
A2780cisR MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEGzV5ZKSzVyPUS4MlnjiIoEsfMAjVMvQSEQvF2= NF3yeY4zPDJyOU[5Ny=>
A2780ZD0473R MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX72clNkUUN3ME22OE436oDLwsJihKk{NjJizszN NF7KdoczPDJyOU[5Ny=>
SKOV-3 M3vISGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjNTWM2OD12Mz605qCKyrIkgJmzMlkh|ryP MV[yOFIxQTZ7Mx?=

... Click to View More Cell Line Experimental Data

In vivo In A2780 tumor xenografts, Carboplatin (60 mg/kg via i.p.) given as single agents shows a modest antitumor effect with the relative tumor volumes on day 6 of 8.4 compared to the control of 11.9, and the day 6 tumor weights relative to control (T/C) of 67%. [1] For the VC8 (Brca2-deficient) xenografts, Carboplatin treatment delays tumor growth and reduces tumor mass by 42% compared to the vehicle group. [3]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: A2780, SKOV3, IGROV-1 and HX62
  • Concentrations: 0-200 μM
  • Incubation Time: 72 hours
  • Method:

    3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assays: Exponentially growing A2780, SKOV3, IGROV-1 and HX62 ovarian cancer cells are plated in 96 well plates. A range of drug concentrations are added and the plates are incubated for 72 hours to allow for 3–4 doubling times. Each experiment is carried out in triplicate. Sulforhodamine B (SRB) assays: Exponentially growing A2780 cells are plated in 96 well microtitre plates. For experiments studying concomitant exposure, cells are exposed to increasing concentrations of both drugs for 96 hours. For experiments studying the effect of sequence of exposure to 17-AAG or carboplatin cells are exposed to increasing concentrations of 17-AAG or carboplatin for 24 hours. A period of 24-hour exposure to the first agent is chosen so that the A2780 cells would be exposed to the first drug for at least one doubling time (18-24 hours). The cells are then washed with sterile phosphate buffered saline and the medium is replenished. Following this, the second drug (to which the cells are not exposed to in the first 24 hours) or medium is added for 96 hours. All experiments are carried out in triplicate. The results of combination studies are analyzed using the well-established principles of median effect analysis method. The effects of the combination are calculated using an in-house spreadsheet.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: The A2780 human ovarian cancer cell line is grown as a subcutaneous xenograft in female athymic NCr nude mice (nu/nu) in each flank.
  • Formulation: Carboplatin is dissolved in 43% ethanol, 33% polypropylene glycol and 24% cremaphor diluted 1:7 with sterile water.
  • Dosages: ≤60 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro Water 14 mg/mL warmed (37.71 mM)
DMSO Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
water
For best results, use promptly after mixing.
14mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 371.25
Formula

C6H12N2O4Pt

CAS No. 41575-94-4
Storage powder
in solvent
Synonyms JM-8, CBDCA, NSC 241240

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03400306 Not yet recruiting Cancer - Ovarian AbbVie May 10 2020 Phase 1
NCT03400306 Not yet recruiting Cancer - Ovarian AbbVie May 10 2020 Phase 1
NCT03811002 Not yet recruiting Limited Stage Lung Small Cell Carcinoma|Stage IIB Lung Cancer AJCC v8|Stage III Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8 National Cancer Institute (NCI) September 6 2019 Phase 2|Phase 3
NCT03811002 Not yet recruiting Limited Stage Lung Small Cell Carcinoma|Stage IIB Lung Cancer AJCC v8|Stage III Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8 National Cancer Institute (NCI) September 6 2019 Phase 2|Phase 3
NCT02487849 Suspended Epithelial Ovarian Cancer|Peritoneal Cancer|Fallopian Tube Cancer Krankenhaus Barmherzige Schwestern Linz August 2019 Phase 2
NCT02487849 Suspended Epithelial Ovarian Cancer|Peritoneal Cancer|Fallopian Tube Cancer Krankenhaus Barmherzige Schwestern Linz August 2019 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Can you advise what solvent to use and the concentration for S1215 for in vitro use?

  • Answer:

    DMSO will affact the activity of platinum agents. For in vitro use, according to our experience in dissolving this compound, we didn't find any solvent can dissolve it alone, but S1215 can be dissolved in co-solvent ethanol:water=1:2 at 15 mg/ml. We didn't test the stablility of the drug in such vehicle, so it is recommended to prepare the solution just before use.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products0

Tags: buy Carboplatin | Carboplatin supplier | purchase Carboplatin | Carboplatin cost | Carboplatin manufacturer | order Carboplatin | Carboplatin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID